Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan.
Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.
Cancer Med. 2021 Feb;10(4):1335-1346. doi: 10.1002/cam4.3737. Epub 2021 Feb 9.
Various biomarkers are being developed for the early diagnosis of cancer and for predicting its prognosis. The aim of this study is to evaluate the diagnostic significance of serum CD109 in head and neck squamous cell carcinoma (HNSCC).
The serum CD109 levels in a total of 112 serum samples collected before and after surgery from 56 HNSCC patients were analyzed with an enzyme-linked immunosorbent assay (ELISA). The clinical factor that showed a statistically significant association with both the preoperative serum CD109 level, and the CD109 index: which was defined as the ratio of the preoperative serum CD109 level to the postoperative serum CD109 level, were assessed. The correlations between the serum CD109 levels and lymph node density (LND), pathological features such as lymphatic invasion, and serum SCC antigen levels were also assessed.
The ELISA measurement revealed that preoperative serum CD109 levels were elevated in patients with node metastasis-positive and stage IV disease, in comparison to those with node metastasis-negative and Stage I+II+III disease, respectively. A multiple regression analysis indicated that serum CD109 level was significantly associated with the node metastasis status. A Spearman's rank correlation analysis also revealed a positive correlation between the preoperative serum CD109 level and LND. Furthermore, the probabilities of the overall and relapse-free survival were significantly lower in patients with a preoperative serum CD109 level of ≥38.0 ng/ml and a CD109 index of ≥1.6, respectively, than in others. There was no significant correlation between the serum CD109 and SCC antigen levels.
The serum CD109 levels were elevated in patients with advanced stage disease, reflecting the node metastasis status. CD109 in sera could be a novel prognostic marker for HNSCC involving lymph node metastasis.
目前正在开发各种生物标志物用于癌症的早期诊断和预测其预后。本研究旨在评估血清 CD109 在头颈部鳞状细胞癌（HNSCC）中的诊断意义。
采用酶联免疫吸附试验（ELISA）分析了 56 例 HNSCC 患者手术前后共 112 份血清样本中的血清 CD109 水平。评估了与术前血清 CD109 水平和 CD109 指数（定义为术前血清 CD109 水平与术后血清 CD109 水平的比值）均呈统计学显著相关的临床因素。还评估了血清 CD109 水平与淋巴结密度（LND）、淋巴浸润等病理特征以及血清 SCC 抗原水平之间的相关性。
ELISA 测量结果显示，与淋巴结转移阴性和 I+II+III 期患者相比，淋巴结转移阳性和 IV 期患者的术前血清 CD109 水平升高。多元回归分析表明，血清 CD109 水平与淋巴结转移状态显著相关。Spearman 秩相关分析还显示，术前血清 CD109 水平与 LND 呈正相关。此外，术前血清 CD109 水平≥38.0ng/ml 和 CD109 指数≥1.6 的患者的总生存率和无复发生存率明显低于其他患者。血清 CD109 与 SCC 抗原水平之间无显著相关性。
晚期疾病患者的血清 CD109 水平升高，反映了淋巴结转移状态。血清 CD109 可能是一种新的涉及淋巴结转移的 HNSCC 预后标志物。
